Shots:
- Dicerna to receive $175M up front, $50M equity investment, $75M for first three years of collaboration and up to $375.5M/ target as development, regulatory and commercialization milestones with royalties on product sales
- Both the companies will retain rights to co-develop and co-commercialize candidates and will explore up to 30 liver cell targets for which Dicerna will be responsible to conduct & fund discovery & preclinical development into clinical for each target while Novo Nordisk to be responsible for all further developments
- The collaboration allows Novo Nordisk to access Dicerna’s GalXC RNAi platform for delivering clinical candidates targeting chronic liver disease, non-alcoholic steatohepatitis (NASH), type 2 diabetes, obesity, and rare diseases
Click here to read full press release/ article | Ref: Novo Nordisk | Image: Finans
